Clinical trials: Crohn Disease
Crohn's Disease
Extension Study of Semapimod 60 mg IV x 3 Days
Study CNI-1493-CD06 is an open, single-arm extension studies to CD03 and CD05. CDAI is the only efficacy measure assessed in this study.
- Trial name
- CD06 (NCT00741910)
- Testing
- Semapimod
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 15 people
- Sponsor
- Ferring Pharmaceuticals
Inflammatory Bowel Disease
A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a chronic inflammatory disease that requires lifelong treatment. This study will asses the concentrations of risankizumab in the breast milk of lactating women with IBD Risankizumab is an…
- Trial name
- NCT06346288
- Testing
- Breast Milk Sampling, Risankizumab
- Where
- 3 sites in United States, Israel
- Volunteers
- 10 people
- Sponsor
- AbbVie
Healthy
Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects
The goal of this clinical trial is to investigate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of BCD-261 after single subcutaneous injection at ascending doses and proposed therapeutic doses…
- Trial name
- NCT06715540
- Testing
- BCD-261, dose 1, BCD-261, dose 2, BCD-261, dose 3
- Where
- Russia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Biocad
Diverticulum, Colon, Colorectal Neoplasms
A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing
The proposed study is a post marketing, observational, retrospective data collection intended to gather and record data on patients treated with the ColonRing device in routine clinical practice at 4-6 centers.
- Conditions
- Diverticulum, Colon, Colorectal Neoplasms, Crohn Disease, Colitis, Ulcerative
- Trial name
- NCT01880918
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- novoGI
Crohn's Disease
Phase II Study of RR110 in Patients With Active Crohn's Disease
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics profile of 1 and 4 mg/kg/day RR110 administrated orally for 8 weeks in patients with active Crohn's disease.
- Trial name
- NCT00417391
- Testing
- RR110 (Tamibarotene)
- Where
- 8 sites in Japan
- Volunteers
- 24 people
- Sponsor
- R&R Inc.
Ulcerative Colitis, Crohn Disease
HMPL004-6599 Phase I Dose-escalating Study
To assess the safety and tolerability of single and multiple doses of HMPL004-6599 in healthy male volunteers
- Trial name
- NCT03597971
- Testing
- HMPL004-6599
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Nutrition Science Partners Limited
Anal Fistula, Crohn's Disease
Treatment of Crohn's Fistula Using a Porcine Intestine Submucosa Graft
Healing anal fistulas in Crohn's patients with an anal fistula plug.
- Trial name
- SurgiSIS AFP (NCT00610207)
- Testing
- Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Cook Group Incorporated
Crohn's Disease
A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in adults with moderately and severely active Crohn's disease (CD).
- Trial name
- U-EXCEL (NCT03345849)
- Testing
- Upadacitinib
- Where
- 432 sites in United States, Argentina and 47 more
- Volunteers
- 526 people
- Sponsor
- AbbVie
Crohn's Disease
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
The primary objective is to determine the efficacy of rifaximin DR also referred to as Extended Intestinal Release (EIR) tablets vs.
- Trial name
- NCT02240121
- Testing
- Rifaximin EIR
- Where
- 72 sites in United States
- Volunteers
- 80 people
- Sponsor
- Bausch Health Americas, Inc.
Colon Neoplasms, Crohn Disease (CD)
Feasibility Study of the SEGER Device in Laparoscopic Gastrointestinal Surgery
This is a first-in-human feasibility study designed to evaluate the safety and performance of the SEGER device in patients undergoing elective laparoscopic gastrointestinal surgery requiring intracorporeal anastomosis.
- Conditions
- Colon Neoplasms, Crohn Disease (CD), Obesity & Overweight
- Trial name
- SEGER-FIH (NCT07508592)
- Testing
- SEGER Device
- Where
- El Salvador
- Volunteers
- 10 people
- Sponsor
- Seger Surgical Solutions
Anemia, Iron-Deficiency, Inflammatory Bowel Disease
Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
The purpose of this study is to compare the efficacy of ferric maltol and intravenous iron (IVI) Ferric Carboxy Maltose in the treatment of iron deficiency anaemia (IDA) and subsequent maintenance of haemoglobin in subjects with…
- Conditions
- Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease
- Trial name
- NCT02680756
- Testing
- Ferric Maltol, Ferric Carboxy Maltose
- Where
- 44 sites in United States, Belgium and 4 more
- Volunteers
- 250 people
- Sponsor
- Shield Therapeutics
Crohn's Disease
Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease
The purpose of this study is to compare changes in Perianal Crohn's Disease following use of locally applied 10% metronidazole ointment and a placebo.
- Trial name
- NCT00509639
- Testing
- 10% Metronidazole Ointment
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 74 people
- Sponsor
- S.L.A. Pharma AG
Crohn's Disease
Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806
This was a multicenter, open-label study to evaluate the human monoclonal anti-TNF-α antibody adalimumab as an effective therapy for maintaining clinical response in pediatric participants with Crohn's disease (CD) and to gather…
- Trial name
- NCT00686374
- Testing
- Adalimumab
- Volunteers
- 100 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn's Disease
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population.
- Trial name
- SECURE (NCT00844285)
- Testing
- Cimzia
- Where
- 197 sites in United States
- Volunteers
- 3,072 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Inflammatory Bowel Disease
Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose
Healthy Normal Single Ascending Dose and Crohn's patient Multiple Ascending Dose
- Trial name
- NCT00868660
- Testing
- ZP1848
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Zealand Pharma
Fibrostenotic Crohn's Disease
STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Many patients with Crohn's disease develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals.
- Trial name
- NCT05843578
- Testing
- AGMB-129
- Where
- 52 sites in United States, Austria and 6 more
- Volunteers
- 103 people
- Sponsor
- Agomab Spain S.L.U.
Crohn's Disease
Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®
This is a post-marketing real-world study designed to evaluate the efficacy and safety of Tabellvi® (Adalimumab Injection) in Chinese adult subjects with moderate to severe active Crohn's disease via a single-arm trial.
- Trial name
- NCT07663526
- Testing
- TyboWe® Adalimumab Injection
- Where
- 7 sites in China
- Volunteers
- 50 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Crohn's Disease
A Study of Vedolizumab in Adults With Crohn's Disease (CD)
The main aim of this study is to see if adults with CD treated with vedolizumab have less symptoms and inflammation of the bowel assessed by ultrasonography.
- Trial name
- SUNRISE (NCT05192863)
- Testing
- No Intervention
- Where
- 10 sites in Canada, Israel and 1 more
- Volunteers
- 72 people
- Sponsor
- Takeda
Crohns Disease
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
To assess the safety and efficacy of intravenous (IV) PDA001 infused every two weeks for up to 5 total infusions in subjects with Crohn's disease who are refractory to one or more standard Crohn's disease therapies.
- Trial name
- NCT01769755
- Testing
- PDA001
- Where
- 12 sites in United States
- Volunteers
- 14 people
- Sponsor
- Celularity Incorporated
Crohn's Disease
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to…
- Trial name
- NCT00338650
- Testing
- adalimumab
- Where
- 97 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Abbott